A Phase III, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Apr 2018
At a glance
- Drugs Besifovir (Primary) ; Levocarnitine; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Sponsors Ildong Pharmaceutical
- 14 Apr 2018 Results over 96 week presented at The International Liver Congress 2018.
- 19 Mar 2018 Planned End Date changed from 1 Jan 2016 to 1 Jan 2023.
- 23 Apr 2017 Status changed from recruiting to active, no longer recruiting, according to results presented at The International Liver Congress 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History